Production of a Chikungunya Vaccine Using a CHO Cell and Attenuated Viral-Based Platform Technology.

ABSTRACT: Vaccinia-based systems have been extensively explored for the development of recombinant vaccines. Herein we describe an innovative vaccinia virus (VACV)-derived vaccine platform technology termed Sementis Copenhagen Vector (SCV), which was rendered multiplication-defective by targeted deletion of the essential viral assembly gene D13L. A SCV cell substrate line was developed for SCV vaccine production by engineering CHO cells to express D13 and the VACV host-range factor CP77, because CHO cells are routinely used for manufacture of biologics. To illustrate the utility of the platform technology, a SCV vaccine against chikungunya virus (SCV-CHIK) was developed and shown to be multiplication-defective in a range of human cell lines and in immunocompromised mice. A single vaccination of mice

SUBMITTER: Eldi P 

PROVIDER: S-EPMC5628773 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature